Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Central Adrenal InsufficiencyMifepristone
Interventions
DRUG

Mifepristone

Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.

Trial Locations (1)

48108

University of Michigan, Ann Arbor

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Corcept Therapeutics

INDUSTRY

lead

Tobias Else

OTHER